Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of strong sales for its blockbuster cancer drug Keytruda, sending the company’s shares up more than 2% before the bell.
Keytruda, the world’s top selling drug in 2023, has been Merck’s key revenue driver over the past few years and is expected to top $30 billion in sales by 2026 before losing exclusivity…
Continue Reading
News Source: arynews.tv
Leave a Reply
You must be logged in to post a comment.